Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.
- Darwich AS Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, University of Manchester, Manchester, UK.
- Ogungbenro K Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, University of Manchester, Manchester, UK.
- Vinks AA Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Powell JR Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
- Reny JL Geneva Platelet Group, School of Medicine, University of Geneva, Geneva, Switzerland.
- Marsousi N Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.
- Daali Y Geneva Platelet Group, School of Medicine, University of Geneva, Geneva, Switzerland.
- Fairman D Clinical Pharmacology Modeling and Simulation, GSK Stevenage, UK.
- Cook J Clinical Pharmacology, Pfizer Inc, Groton, Connecticut, USA.
- Lesko LJ Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida at Lake Nona (Orlando), Orlando, Florida, USA.
- McCune JS University of Washington Department of Pharmaceutics and Fred Hitchinson Cancer Research Center Clinical Research Division, Seattle, Washington, USA.
- Knibbe C Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, the Netherlands and Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, the Netherlands.
- de Wildt SN Department of Pharmacology and Toxicology, Radboud University, Nijmegen, the Netherlands.
- Leeder JS Division of Pediatric Pharmacology and Medical Toxicology, Department of Pediatrics, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA.
- Neely M University of Southern California and the Children's Hospital of Los Angeles, Los Angeles, California, USA.
- Zuppa AF Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Vicini P Clinical Pharmacology, Pharmacometrics and DMPK, MedImmune, Cambridge, UK.
- Aarons L Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, University of Manchester, Manchester, UK.
- Johnson TN Certara, Blades Enterprise Centre, Sheffield, UK.
- Boiani J Epstein Becker & Green, Washington, DC, USA.
- Rostami-Hodjegan A Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, University of Manchester, Manchester, UK.
- 2017-02-10
Published in:
- Clinical pharmacology and therapeutics. - 2017
Cost-Benefit Analysis
Delivery of Health Care, Integrated
Forecasting
Humans
Models, Biological
Pharmaceutical Preparations
Precision Medicine
English
Patient groups prone to polypharmacy and special subpopulations are susceptible to suboptimal treatment. Refined dosing in special populations is imperative to improve therapeutic response and/or lowering the risk of toxicity. Model-informed precision dosing (MIPD) may improve treatment outcomes by achieving the optimal dose for an individual patient. There is, however, relatively little published evidence of large-scale utility and impact of MIPD, where it is often implemented as local collaborative efforts between academia and healthcare. This article highlights some successful applications of bringing MIPD to clinical care and proposes strategies for wider integration in healthcare. Considerations are brought up herein that will need addressing to see MIPD become "widespread clinical practice," among those, wider interdisciplinary collaborations and the necessity for further evidence-based efficacy and cost-benefit analysis of MIPD in healthcare. The implications of MIPD on regulatory policies and pharmaceutical development are also discussed as part of the roadmap.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1002/cpt.659
- PMID 28182269
- Persistent URL
- https://sonar.ch/global/documents/269029
Statistics
Document views: 57
File downloads:
- Full-text: 0